Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 4 of the 11 sources its claims cite were checked for support.
Abstract
The inner membrane complex (IMC) of Toxoplasma gondii as a peripheral membrane system has unique and critical roles in parasite replication, motility and invasion. Disruption of IMC sub-compartment protein produces a severe defect in T. gondii endodyogeny, the form of internal cell budding. In this study, we generated T. gondii virus-like particle particles (VLPs) containing proteins derived from IMC, and investigated their efficacy as a vaccine in mice. VLP vaccination induced Toxoplasma gondii-specific total IgG, IgG1 and IgG2a antibody responses in the sera and IgA antibody responses in the feces. Upon challenge infection with a lethal dose of T. gondii (ME49), all vaccinated mice survived, whereas all naïve control mice died. Vaccinated mice showed significantly reduced cyst load and cyst size in the brain. VLP vaccination also induced IgA and IgG antibody responses in feces and intestines, and antibody-secreting plasma cells, mixed Th1/Th2 cytokines and CD4+/CD8+ T cells from spleen. Taken together, these results indicate that non-replicating VLPs containing inner membrane complex of T. gondii represent a promising strategy for the development of a safe and effective vaccine to control the spread of Toxoplasma gondii infection.
Overview
CoChat Summary
## TL;DR
This mouse study tested a virus-like particle (VLP) vaccine carrying *Toxoplasma gondii* inner membrane complex proteins and found strong systemic and mucosal immune responses. Vaccinated mice survived a lethal challenge and had reduced brain cyst burden, suggesting the VLP platform is a promising vaccine candidate.
## Key findings
- Intranasal vaccination with the VLPs induced *T. gondii*-specific serum antibodies: total IgG, IgG1, and IgG2a, plus mucosal IgA in feces.
- After challenge with *T. gondii* ME49, vaccinated mice had significantly higher antibody responses in serum, feces, and intestines; the paper reports *P* < 0.05 for these increases.
- Vaccination reduced brain parasite burden: cyst count and cyst size were significantly decreased, with a reported reduction rate of 65%.
- Protection was strong: all vaccinated mice survived a lethal challenge with 120 cysts, while all naïve control mice died; in the 30-cyst challenge, vaccinated mice had 100% survival and controls had 60% survival.
## Methods
- Design: preclinical mouse vaccination-challenge study using non-replicating VLPs displaying *T. gondii* IMC protein with influenza M1 as core protein.
- Sample/sample size: female BALB/c mice, 6–8 weeks old; groups of *n* = 6 per group.
- Main analysis: mice were intranasally immunized twice with 100 μg total VLP protein at 4-week intervals, then orally challenged with *T. gondii* ME49 (30 or 120 cysts); outcomes included ELISA for IgG/IgG1/IgG2a/IgA, brain cyst counts and size, survival, body weight, ASC assays, cytokines (IFN-γ, IL-6, IL-10), and CD4+/CD8+ T cells.
## Limitations
- The paper states that there is no standard protocol for evaluating *T. gondii* vaccines in animal models, so the challenge isolate and dose vary across studies.
- Evident from the text: the study is limited to mice and does not test human efficacy or safety.
- Evident from the text: the paper does not report long-term protection beyond the 1-month postchallenge assessments described.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
4 Valid · 0 Not valid · 6 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The inner membrane complex (IMC) of Toxoplasma gondii as a peripheral membrane system has unique and critical roles in parasite replication, motility and invasion.”
§ Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii > Abstract
What the sources say
- Supportedcites [8] Beck JR, Rodriguez-Fernandez IA, de Leon JC, Huynh MH, Carruthers VB, Morrissette NS, et al A novel family of Toxoplasma IMC proteins displays a hierarchical organization and functions in coordinating parasite division. PLoS Pathog. 2010; 6: e1001094 10.1371/journal.ppat.1001094 20844581 PMC2936552 source
The Discussion section, “The IMC in apicomplexan parasites,” explicitly says that the IMC has unique and critical roles in parasite replication, motility, and invasion. The Abstract also describes it as a peripheral membrane system. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since vaccine study reported on T. gondii have not been able to induce effective protective immunity [26], developing effective vaccine against T. gondii infection would have significant impact.”
§ Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii > Discussion
What the sources say
- Supportedcites [26] Jongert E, Roberts CW, Gargano N, Förster-Waldl E, Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz. 2009; 104: 252– 266. 19430651 source
The Abstract (p. 1) states directly that 'regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector', which is what the citing sentence attributes. The Discussion reinforces it: sterile immunity was not achieved by the prime-boost regimen 'or by any of the other up-to-date experimental settings', and 'Sterile immunity and complete protection against acute transplacental infection and protection against congenital disease has not been obtained in mice, despite intensive efforts'. The source bounds the statement with the caveat that a few live, attenuated strains conferred protective immunity (measured by absence of tissue cysts) and that sterile immunity was achieved in pigs (Kringel et al. 2004, Section 'Inactivated parasites...'), so the claim's blanket wording is slightly stronger than the source's qualified generalisation, but the attributed point is the source's own. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“significantly decreased cyst counts and cyst sizes in brain were detected in mice upon challenge infection compared to non-immunized mouse controls (Reduction rate: 65%; Fig 5A and 5B, *P < 0.05)”
§ Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii > Results > Immunization with VLPs confers protection from T. gondii challenge infection
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“higher levels of IgA and IgG responses in feces were observed after boost compared to naïve control”
§ Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii > Results > Immunization with VLPs elicits antibody responses
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significantly higher levels of IgG, IgG1 and IgG2a antibodies specific to T. gondii were secreted into culture supernatants by spleen cells of immunized mice than from cells derived from mice infected only with T. gondii”
§ Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii > Results > Infection with Toxoplasma gondii induces a marked anti-T. gondii antibody-secreting cell response
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
32 more claims
Create a free account to see all 54 claims and to verify the 5 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 9
- The quote only partly states this claim. 2
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Toxoplasmosis of Animals and Man
Frenkel, J. K., Dubey, J. P., & Beattie, C. P. (1989) · The Journal of Parasitology · doi:10.2307/3283074 · Cited by 1,697
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896 · cited 1×
“Chimeric recombinant VLPs containing Plasmodium falciparum circumsporozoite protein antigen fused to hepatitis B surface antigen has reached a Phase III clinical trial of malaria vaccine, in which 30–50% protection was elicited, which is considered to be significant [22].”
BackgroundToxoplasmosis: A history of clinical observations
Weiss, L. M., & Dubey, J. P. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.02.004 · Cited by 885
Quan, F.-S., Huang, C., Compans, R. W., & Kang, S.-M. (2007) · Journal of Virology · doi:10.1128/jvi.02052-06 · Cited by 313
Self-citationKang, H., Remington, J. S., & Suzuki, Y. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2629 · Cited by 250
Beck, J. R., Rodriguez-Fernandez, I. A., Cruz de Leon, J., Huynh, M.-H., Carruthers, V. B., Morrissette, N. S., & Bradley, P. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001094 · Cited by 217
Pathophysiology of toxoplasmosis
Frenkel, J. K. (1988) · Parasitology Today · doi:10.1016/0169-4758(88)90018-x · Cited by 206
Vaccines against Toxoplasma gondii: challenges and opportunities
Jongert, E., Roberts, C. W., Gargano, N., Förster-Waldl, E., & Petersen, E. (2009) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762009000200019 · Cited by 205 · cited 1×
“gondii have not been able to induce effective protective immunity [26], developing effective vaccine against T.”
BackgroundPerrone, L. A., Ahmad, A., Veguilla, V., Lu, X., Smith, G., Katz, J. M., Pushko, P., & Tumpey, T. M. (2009) · Journal of Virology · doi:10.1128/jvi.00207-09 · Cited by 143 · cited 1×
“It is likely that activated T-helper cells activate B cells and the interaction between the Thelper cells and B-cells cause the B-cells to differentiate into plasma cells and memory cells [25].”
BackgroundDevelopment of a vaccine for toxoplasmosis: current status
Bhopale, G. M. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(03)00048-0 · Cited by 135
Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice
Quan, F.-S., Kim, Y., Lee, S., Yi, H., Kang, S.-M., Bozja, J., Moore, M. L., & Compans, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir474 · Cited by 125
Self-citationDeficient Humoral Responses Underlie Susceptibility to Toxoplasma gondii in CD4-Deficient Mice
Johnson, L. L., & Sayles, P. C. (2002) · Infection and Immunity · doi:10.1128/iai.70.1.185-191.2002 · Cited by 105
Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay
Slifka, M. K., & Ahmed, R. (1996) · Journal of Immunological Methods · doi:10.1016/s0022-1759(96)00146-9 · Cited by 102
Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice
Quan, F., Vunnava, A., Compans, R. W., & Kang, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009161 · Cited by 101
Self-citationCellular immunity and memory to respiratory virus infections
Woodland, D. L., Hogan, R. J., & Zhong, W. (2001) · Immunologic Research · doi:10.1385/ir:24:1:53 · Cited by 97 · cited 1×
“A fraction of memory B lymphocytes developed in the secondary lymphoid organs is routed to the spleen, resides there as long-lived plasma cells, and secretes antibodies, maintaining long-term serum antibody levels [23, 24].”
BackgroundA bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs
Quan, F., Steinhauer, D. A., Huang, C., Ross, T. M., Compans, R. W., & Kang, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.055 · Cited by 94
Self-citationNew antibacterials for the treatment of toxoplasmosis; a patent review
Rodríguez, J. B., & Szajnman, S. H. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.668886 · Cited by 67
Glor, S. B., Edelhofer, R., Grimm, F., et al. (2013) · Parasites & Vectors · doi:10.1186/1756-3305-6-85 · Cited by 66
Quan, F. S., Yoo, D.-G., Song, J.-M., Clements, J. D., Compans, R. W., & Kang, S.-M. (2009) · Journal of Virology · doi:10.1128/jvi.02035-08 · Cited by 64
Self-citationFang, R., Feng, H., Nie, H., Wang, L., Tu, P., Song, Q., Zhou, Y., & Zhao, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.12.005 · Cited by 43
Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset, F., Vazquez, T., & Bellier, B. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1046440 · Cited by 43
Hassan, I. A., Wang, S., Xu, L., et al. (2014) · Parasites & Vectors · doi:10.1186/1756-3305-7-431 · Cited by 37
Vercammen, M. J., Scorza, T., BOUHDIDI, A. E., et al. (1999) · Parasite Immunology · doi:10.1046/j.1365-3024.1999.00256.x · Cited by 25
Sánchez, V. R., Fenoy, I. M., Picchio, M. S., Soto, A. S., Arcon, N., Goldman, A., & Martin, V. (2015) · Acta Tropica · doi:10.1016/j.actatropica.2015.07.013 · Cited by 20
Tonkin, M. L., Beck, J. R., Bradley, P. J., & Boulanger, M. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548891 · Cited by 16
Chu, K., Kim, S. ‐., Lee, S. ‐., Lee, H. ‐., Joo, K. H., Lee, J. ‐., Lee, Y., Zheng, S., & Quan, F. (2014) · Parasite Immunology · doi:10.1111/pim.12125 · Cited by 11
Self-citation
Cited by
Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development
Chu, K.-B., & Quan, F.-S. (2021) · Vaccines · doi:10.3390/vaccines9050413 · Cited by 92
“gondii ME49 strain through the intraperitoneal [79] or oral route [80].”
BackgroundSelf-citationVirus-Like Particles as an Instrument of Vaccine Production
Syomin, B. V., & Ilyin, Y. V. (2019) · Molecular Biology · doi:10.1134/s0026893319030154 · Cited by 98
Toxoplasma gondii vaccine candidates: a concise review
Mamaghani, A. J., Fathollahi, A., Arab-Mazar, Z., kohansal, K., Fathollahi, M., Spotin, A., Bashiri, H., & Bozorgomid, A. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02998-9 · Cited by 51
Recent progress in microneme-based vaccines development againstToxoplasma gondii
Foroutan, M., Zaki, L., & Ghaffarifar, F. (2018) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2018.7.2.93 · Cited by 54
Lee, S., Kang, H., Lee, D., Kang, S., & Quan, F. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.016 · Cited by 40
Self-citation
Metadata
- Authors
- Lee, D. H., Lee, S. H., Kim, A. R., & Quan, F. S.
- Affiliations
- Kyung Hee University (KR)
- Corresponding author
- Quan, Fu Shi
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-08-22
- Volume
- 11
- Issue
- 8
- Pages
- e0161231
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4993474
- OpenAlex
- W2517189574
- Cited by
- 36
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 3 · 2017: 4
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-03-21)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF-2014R1A2A2A01004899)
- Rural Development Administration (315030031-HD020)
- Ministry of Health and Welfare (HI15C2928)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Coccidia and coccidiosis research
- Life Sciences › Immunology and Microbiology › Parasitology › Parasitic infections in humans and animals
- Keywords
- Toxoplasma gondii, toxoplasmosis vaccine, virus-like particles, inner membrane complex, endodyogeny, antibody response, IgA, IgG, Th1/Th2 cytokines, CD4+CD8+ T cells, ME49 strain, non-replicating vaccine
- MeSH terms
- Animals, Antibodies, Protozoan, Brain, Feces, Female, Immunoglobulin A, Immunoglobulin G, Intestines, Mice, Inbred C57BL, Toxoplasma, Toxoplasmosis, Animal, Vaccination, Protozoan Proteins, Survival Analysis, Protozoan Vaccines, CD4-CD8 Ratio, Mice, Nanoparticles, Th1-Th2 Balance, Vaccines, Virus-Like Particle
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.